Optimization of the k2′ Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2

Background: This study explores different approaches for estimating the clearance rate of reference tissue (k2') parameter, used for pharmacokinetic modelling using the simplified reference tissue model 2 (SRMT2) and its effect on the binding potential (BPnd) of 11C-labelled Pittsburgh Compound B (PIB) PET scans. Methods: Thirty subjects underwent a dynamic PIB PET scan and were classified as PIB positive (+) or negative (-). Thirteen regions were defined from where to estimate k2': whole masked imagebrain, eight anatomical based on the Hammer’s atlas, one SPM voxel-based comparison between groups, and three using different BPnd(SRTM) thresholds. Results: The different approaches resulted in distinct k2' estimations. The median value of the estimated k2' across all subjects was of 0.057. In general, PIB+ subjects presented smaller k2' estimates than this median, and PIB-, larger. Furthermore, only grey matter and SPMthreshold and white matter methods resulted in non-significant bigger differences between groups in the k2' estimations. A sensitivity analysis was done by fixing k2' to a range of values and assessing the effects on BPnd(SRTM2), and a non-linear relationship between the parameters was observed. Furthermore, Tthreshold approaches yielded the best correlation between BPnd(SRTM) and BPnd(SRTM2) for both groups (R²=0.85 for PIB+, and R²=0.88 for PIB-). Lastly, sensitivity analysis shows that overestimating k2' values resulted in less bias in the BPnd(SRTM2) estimates. Conclusion: Results suggested that setting a threshold on BPnd(SRTM) might be the best method for estimating k2' in voxel-based modelling approaches, while the use of a white matter region of interest might be a better option for volume of interest-based analysis.

[1]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[2]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[3]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  C. Weiller,et al.  Assessment of Striatal Dopamine D2/D3 Receptor Availability with PET and 18F-Desmethoxyfallypride: Comparison of Imaging Protocols Suited for Clinical Routine , 2012, The Journal of Nuclear Medicine.

[5]  Richard E Carson,et al.  Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin Transporter , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[7]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[8]  Nelleke Tolboom,et al.  Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.

[9]  M. Hüll,et al.  Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.

[10]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[11]  O. Lopez,et al.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study , 2012, Acta Neuropathologica.

[12]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[13]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[14]  D. Selkoe,et al.  DIFFUSE SENILE PLAQUES: THE CAUDATE AND PUTAMEN AS A MODEL , 1989 .

[15]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[16]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[17]  R. Boellaard,et al.  Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies , 2019, PloS one.

[18]  R. Boellaard,et al.  Parametric Imaging of [11C]Flumazenil Binding in the Rat Brain , 2017, Molecular Imaging and Biology.

[19]  Yun Zhou,et al.  Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease , 2007, NeuroImage.

[20]  Richard E Carson,et al.  Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in Humans , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Oscar L Lopez,et al.  Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET , 2015, The Journal of Nuclear Medicine.

[23]  R. Boellaard,et al.  Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  S. Hirai,et al.  Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.

[25]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[26]  Ove Almkvist,et al.  Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[27]  Christine M Sandiego,et al.  Reference Region Modeling Approaches for Amphetamine Challenge Studies with [11C]FLB 457 and PET , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  Osama Sabri,et al.  Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol , 2017, The Journal of Nuclear Medicine.

[29]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  Chris Buckley,et al.  Parametric imaging and quantitative analysis of the PET amyloid ligand [18F]flutemetamol , 2015, NeuroImage.

[31]  Ronald Boellaard,et al.  Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study , 2018, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  A. Lammertsma,et al.  Forward to the Past: The Case for Quantitative PET Imaging , 2017, The Journal of Nuclear Medicine.

[33]  R. Boellaard,et al.  Parametric Binding Images of the TSPO Ligand 18F-DPA-714 , 2016, The Journal of Nuclear Medicine.

[34]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[35]  A. Hammers,et al.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease , 2016 .

[36]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[37]  C. Rowe,et al.  Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.

[38]  L. Ferrucci,et al.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.

[39]  R. Boellaard,et al.  Parametric Imaging of [ 11 C ] Flumazenil Binding in the Rat Brain , 2017 .